

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/188844 A3

(51) International Patent Classification:

A61P 25/00 (2006.01) C07K 14/33 (2006.01)
A61P 25/06 (2006.01)

(21) International Application Number:

PCT/US2021/023046

(22) International Filing Date:

18 March 2021 (18.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/991,185 18 March 2020 (18.03.2020) US

(71) Applicant: **REVANCE THERAPEUTICS, INC.**
[US/US]; 7555 Gateway Blvd., Newark, CA 94560 (US).

(72) Inventors: **CHEHRENAME, Mahan**; 9844 Beach Mill Road, Great Falls, VA 22066 (US). **SILBERSTEIN, Stephen**; 50 South 16th Street, Philadelphia, PA 19102 (US). **BURSTEIN, Rami**; Center for Life Science CL-649, 3 Blackfan Circle, Boston, MA 02115 (US). **MCALLISTER, Peter**; 7 Sammis Street, Rowayton, CT 06853 (US). **MATTHEW, Paul**; 71 Messina Woods Drive, Braintree, MA 02184 (US). **BLUMENFELD, Andrew**; 336 Ocean View Avenue, Del Mar, CA 92014 (US). **AILANI, Jessica**; 1051 Gelston Circle, McClean, VA 22102 (US). **DODICK, David**; 11392 East Caribbean Lane, Scottsdale,


AZ 85255 (US). **RUBIO, Roman**; 722 Esther Lane, Redwood City, CA 94062 (US).

(74) Agent: **SONNENFELD, Kenneth** et al.; Ballard Spahr LLP, 999 Peachtree Street, Suite 1600, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES



The letters used are:

F - Frontal lobe
T - Temporal lobe
C - Central lobe
P - Parietal lobe
O - Occipital lobe

"Z" refers to an electrode placed on the mid-line.

FIG. 1

(57) Abstract: Provided is an invention based on methods to treat or prevent headaches with injectable compositions comprising botulinum toxin that may be administered using an injection paradigm that provides botulinum toxin at one or more locations of neuronal activity associated with EEG detectable brain cortical electrical activity to a subject suffering from such malady. Co-therapeutics therewith are also disclosed.

[Continued on next page]

WO 2021/188844 A3

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

25 November 2021 (25.11.2021)